Burney Co. Grows Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Burney Co. grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 8.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,057 shares of the medical equipment provider's stock after purchasing an additional 3,416 shares during the period. Burney Co. owned approximately 0.07% of Lantheus worth $3,618,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after acquiring an additional 394,837 shares during the last quarter. Farallon Capital Management LLC raised its position in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock worth $92,316,000 after buying an additional 1,269,900 shares during the last quarter. Reinhart Partners LLC. increased its position in shares of Lantheus by 8.4% during the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock valued at $91,517,000 after purchasing an additional 114,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Lantheus by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider's stock valued at $52,077,000 after purchasing an additional 7,590 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Activity at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now owns 62,557 shares of the company's stock, valued at $4,990,171.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold a total of 41,193 shares of company stock valued at $3,949,202 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LNTH shares. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Mizuho upped their price objective on Lantheus from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, May 3rd. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Finally, Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $119.00.

Lantheus Price Performance

LNTH stock traded down $4.90 during trading on Thursday, hitting $104.81. The company had a trading volume of 1,037,298 shares, compared to its average volume of 1,050,587. The company has a fifty day moving average price of $99.11 and a two-hundred day moving average price of $79.05. The company has a current ratio of 4.68, a quick ratio of 4.55 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market cap of $7.26 billion, a P/E ratio of 15.88 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same period in the previous year, the firm posted $1.40 earnings per share. The firm's revenue was up 22.5% on a year-over-year basis. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.